Markets:

Overview

News

Currencies

International

Treasuries

Neumora Therapeutics, Inc. - Common Stock (NQ:NMRA)

2.275 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neumora Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Class Action Announcement for Neumora Therapeutics, Inc. (NMRA): Kessler Topaz Meltzer & Check, LLP Announces That a Securities Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc.

February 13, 2025

RADNOR, PA - February 13, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora...

Via TheNewswire.com

Topics Lawsuit

Neumora Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NMRA

February 13, 2025

From Robbins LLP

Via GlobeNewswire

Neumora Therapeutics Announces Leadership Transition

February 13, 2025

From Neumora Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

NMRA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 12, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 12, 2025

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

February 12, 2025

From The Schall Law Firm

Via Business Wire

NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) INVESTOR ALERT: Investors With Large Losses in Neumora Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

February 11, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

NMRA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces That Neumora Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

February 08, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – NMRA

February 06, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics

February 06, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Neumora Therapeutics, Inc. – NMRA

February 06, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

Rivian Automotive, Cerence, Nu Skin Enterprises And Other Big Stocks Moving Higher On Friday ↗

January 03, 2025

Via Benzinga

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA

January 02, 2025

From DJS Law Group

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

January 02, 2025

Via Benzinga

Crude Oil Surges 2%; Tesla Shares Plummet ↗

January 02, 2025

Via Benzinga

Nasdaq Dips Over 100 Points; Unity Software Shares Jump ↗

January 02, 2025

Via Benzinga

Dow Surges Over 300 Points; US Initial Jobless Claims Decline ↗

January 02, 2025

Via Benzinga

Topics Stocks

Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops ↗

January 02, 2025

The company said it plans to investigate a positive signal from female patients.

Via Investor's Business Daily

Neumora Therapeutics, XPeng And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

January 02, 2025

Via Benzinga

Neumora Therapeutics Depression Drug Fails In First Of Three Pivotal Phase 3 Trials ↗

January 02, 2025

Neumora's KOASTAL-1 study results show navacaprant missed key goals in major depressive disorder. Additional studies and updates are anticipated.

Via Benzinga

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder

January 02, 2025

From Neumora Therapeutics, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 18, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 12, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

Neumora Therapeutics to Participate in Upcoming Conferences in November

November 06, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

November 05, 2024

Via Benzinga

Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

October 29, 2024

From Neumora Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 21, 2024

Via Benzinga

Neumora Therapeutics to Host Key Opinion Leader Roundtable to Discuss the Potential of Navacaprant in Neuropsychiatric Disorders

August 14, 2024

Roundtable discussion to take place on Thursday, September 12 at 8:00 a.m. ET

From Neumora Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.